QuickView for BIRB796 (compound)

1. CD8+ T-cell subsets stimulated with anti-CD3 antibodies and IL2 in combination with BIRB796
2. L1000 CMAP - Embryonic stem HUES3 cells treated with small molecule perturbagens
3. L1000 CMAP - T-cell ALL JURKAT cells treated with small molecule perturbagens
4. L1000 CMAP - Bone marrow CD34 cells treated with small molecule perturbagens
5. L1000 CMAP - Umbilical vein endothelial HUVEC cells treated with small molecule perturbagens

1. BIRB796, an Inhibitor of p38 Mitogen-Activated Protein Kinase, Inhibits Proliferation and Invasion i…
2. Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duratio…
3. The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer.
4. BIRB 796 has Distinctive Anti-inflammatory Effects on Different Cell Types.
5. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherap…

There were no clinical trials for BIRB796